IMDX vs MYGN: stock comparison and AI forecast
Insight Molecular Diagnostics Inc. (IMDX) and Myriad Genetics Inc (MYGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IMDX Insight Molecular Diagnostics Inc.
- Price
- $2.49 -49.8% · 6M
- Market Cap
- $81M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MYGN Myriad Genetics Inc
- Market Cap
- $566M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- MYGN is 6.9 times larger than IMDX by market capitalization ($566M against $81M).
- Both companies share the SEC industry classification In Vitro & In Vivo Diagnostic Substances.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IMDX | MYGN |
|---|---|---|
| Market Cap | $81M | $566M |
| P/B Ratio | – | 2.11x |
| EPS | $-1.66 | $-4.58 |
| Book Value/Share | – | $2.81 |
| Revenue/Share | $0.05 | $8.40 |
| FCF/Share | $-0.94 | – |
Profitability & Margins
| Metric | IMDX | MYGN |
|---|---|---|
| ROA | -167.6% | – |
| ROIC | – | -24.4% |
| Gross Margin | 48.5% | 68.3% |
| Operating Margin | -3070.7% | -14.3% |
| Net Margin | -3013.4% | – |
| EBT Margin | -2751.5% | -16.1% |
| Tax Rate | 0.0% | 0.1% |
Financial Health
| Metric | IMDX | MYGN |
|---|---|---|
| Current Ratio | 2.00x | 1.98x |
| Quick Ratio | 1.98x | 1.77x |
| D/E Ratio | – | 1.26x |
| Financial Leverage | – | 2.26x |
| Interest Coverage | 570.1x | -11.7x |
| Working Capital | $10M | $134M |
Cash Flow
| Metric | IMDX | MYGN |
|---|---|---|
| Operating Cash Flow | -$27M | -$14M |
| Free Cash Flow | -$31M | – |
| Capital Spending | -$4M | – |
| FCF/Sales | -1884.9% | – |
| CapEx/Sales | 239.4% | – |
Operational Efficiency
| Metric | IMDX | MYGN |
|---|---|---|
| Asset Turnover | 0.06x | 1.32x |
| Receivables Turnover | 8.5x | 7.6x |
| Inventory Turnover | 4.1x | 8.9x |
| Fixed Assets Turnover | 0.3x | 7.7x |
| Days Sales Outstanding | 43 days | 48 days |
| Days Inventory | 88 days | 41 days |
| Payables Period | 796 days | 40 days |
| Cash Conversion Cycle | -665 days | 49 days |
Income Statement
| Metric | IMDX | MYGN |
|---|---|---|
| Total Revenue | $2M | $804M |
| Operating Income | -$50M | -$115M |
| Net Income | -$49M | – |
| R&D Expense | $19M | $104M |
| SG&A Expense | $24M | $604M |
| Cost of Goods Sold | $860K | $254M |
Dividend & Shareholder Information
| Metric | IMDX | MYGN |
|---|---|---|
| Shares Outstanding | 33M | 96M |
IMDX vs MYGN: stock comparison and AI forecast
Which is bigger, IMDX or MYGN?
MYGN is 6.9 times larger than IMDX by market capitalization ($566M against $81M).
Which one does Intratio's AI model rank higher, IMDX or MYGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.